Gilead Sciences | GILD - Assets


Gilead Sciences reported $51.41B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 130.29B 1.23B Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026